News

Brii Biosciences Limited, a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, and TSB…
Read More...

Roche announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) and granted Priority Review for Lunsumio (mosunetuzumab),…
Read More...

Turnstone Biologics Corp., a clinical-stage biotechnology company developing next-generation immunotherapies to treat and cure solid tumors, and Moffitt Cancer Center (“Moffitt”), a…
Read More...

Evotec SE announced that the strategic transaction to acquire Rigenerand Srl, signed in May 2022, has been completed. Based out of Medolla, Italy, the cell technology company with…
Read More...

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo), including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluation in relapsed…
Read More...

CureVac N.V. announced that it has moved to assert its intellectual property rights, accumulated over more than two decades of pioneering work in mRNA technology, which contributed to…
Read More...

Mogrify Limited and Astellas Pharma Inc. announced that they have executed a collaborative research agreement on in vivo regenerative medicine approaches to address sensorineural…
Read More...

Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced that the European Commission (EC)…
Read More...

ProteoNic BV and FyoniBio GmbH announced they have entered into a technology licensing agreement. Under the agreement, FyoniBio gains worldwide, non-exclusive commercial rights for…
Read More...

Sanofi Global Health announces the launch of Impact, a new brand of standard of care medicines produced by Sanofi dedicated for nonprofit distribution to at-risk populations in the …
Read More...

Lonza announced plans to construct a large-scale commercial drug product fill and finish facility in Stein (CH). The investment will enable the company to provide customers with a…
Read More...

Vaxart, Inc. announced an agreement with hVIVO Services Limited, a subsidiary of Open Orphan plc under which hVIVO will conduct a characterization study and, if successful, develop a…
Read More...

Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical development in oncology, announced that the U.S. Food and Drug Administration (FDA)…
Read More...

Twist Bioscience Corporation and Ildong Pharmaceutical announced an agreement under which Ildong will license a suite of Twist VHH antibody libraries to use to discover and develop…
Read More...

Blueprint Medicines Corporation announced strategic financing collaborations with Sixth Street and Royalty Pharma for up to $1.25 billion, bringing significant non-dilutive, low-cost…
Read More...

Oxford Biomedica plc announces that it has signed a new three year Master Services & Development Agreement with AstraZeneca UK Ltd which would facilitate potential future…
Read More...

GSK plc announced it has completed the acquisition of Sierra Oncology, Inc. (Sierra Oncology), a California-based biopharmaceutical company focused on targeted therapies for the…
Read More...

Brii Biosciences Limited announced that it exercised its option to acquire exclusive development and commercialization rights for VIR-3434 in Greater China as part of its broader…
Read More...

Pfizer Inc. announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of PAXLOVID (nirmatrelvir tablets and ritonavir…
Read More...

Agilent Technologies Inc. announced a collaboration agreement with APC Ltd., in which the companies commit to working towards combining their technologies to provide unique workflows to…
Read More...